The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multi-institution phase I trial of ruxolitinib in chronic myelomonocytic leukemia (CMML).
 
Eric Padron
Honoraria - Incyte; Novartis
Research Funding - Cell Therapeutics (Inst); FORMA Therapeutics (Inst); Incyte (Inst)
 
Amy Elizabeth Dezern
No Relationships to Disclose
 
Kris Vaddi
Employment - Incyte
 
Peggy A Scherle
Employment - Incyte
Stock and Other Ownership Interests - Incyte
Patents, Royalties, Other Intellectual Property - Incyte
 
Qing Zhang
No Relationships to Disclose
 
Yan Ma
No Relationships to Disclose
 
Maria Balasis
No Relationships to Disclose
 
Sara Tinsley
No Relationships to Disclose
 
Hanadi Ramadan
No Relationships to Disclose
 
Casandra Zimmerman
No Relationships to Disclose
 
David P. Steensma
Stock and Other Ownership Interests - ARIAD; Synta
Consulting or Advisory Role - Amgen; Celgene; Genoptix; Incyte; Novartis
 
Gail J. Roboz
No Relationships to Disclose
 
Jeffrey E. Lancet
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Celator; Celgene; KaloBios; Seagen; Shire
Research Funding - Celgene (Inst); Pfizer (Inst)
 
Alan F. List
No Relationships to Disclose
 
Mikkael A. Sekeres
No Relationships to Disclose
 
Rami S. Komrokji
No Relationships to Disclose